Avidity Biosciences Inc
NASDAQ:RNA
Cash Flow Statement
Cash Flow Statement
Avidity Biosciences Inc
Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||||||||||
Net Income |
(28)
|
(34)
|
(45)
|
(44)
|
(62)
|
(78)
|
(96)
|
(118)
|
(128)
|
(148)
|
(162)
|
(174)
|
(192)
|
(193)
|
(202)
|
(212)
|
(229)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
|
Stock-Based Compensation |
1
|
2
|
3
|
4
|
8
|
11
|
14
|
17
|
20
|
22
|
24
|
27
|
30
|
33
|
36
|
38
|
0
|
|
Other Non-Cash Items |
8
|
8
|
9
|
5
|
8
|
11
|
14
|
17
|
20
|
22
|
25
|
27
|
27
|
27
|
27
|
27
|
27
|
|
Cash Interest Paid |
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Change in Working Capital |
17
|
(0)
|
1
|
2
|
4
|
(4)
|
(1)
|
5
|
3
|
12
|
13
|
10
|
8
|
(5)
|
(1)
|
64
|
58
|
|
Cash from Operating Activities |
(3)
N/A
|
(26)
-909%
|
(35)
-35%
|
(37)
-6%
|
(50)
-34%
|
(70)
-41%
|
(82)
-17%
|
(95)
-16%
|
(105)
-10%
|
(112)
-7%
|
(123)
-10%
|
(136)
-11%
|
(156)
-14%
|
(170)
-9%
|
(175)
-3%
|
(119)
+32%
|
(140)
-18%
|
|
Investing Cash Flow | ||||||||||||||||||
Capital Expenditures |
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(4)
|
(4)
|
(5)
|
(4)
|
(3)
|
(4)
|
(3)
|
(4)
|
(4)
|
(3)
|
|
Other Items |
0
|
0
|
0
|
(7)
|
0
|
(3)
|
(3)
|
(79)
|
(254)
|
(273)
|
(263)
|
(187)
|
(206)
|
(143)
|
(185)
|
(126)
|
36
|
|
Cash from Investing Activities |
(0)
N/A
|
(0)
+52%
|
(1)
-708%
|
(8)
-703%
|
(8)
-7%
|
(5)
+35%
|
(5)
+1%
|
(83)
-1 434%
|
(257)
-212%
|
(278)
-8%
|
(266)
+4%
|
(190)
+29%
|
(210)
-11%
|
(146)
+30%
|
(189)
-29%
|
(130)
+31%
|
33
N/A
|
|
Financing Cash Flow | ||||||||||||||||||
Net Issuance of Common Stock |
75
|
373
|
373
|
301
|
299
|
1
|
167
|
188
|
212
|
252
|
127
|
346
|
344
|
343
|
302
|
63
|
191
|
|
Net Issuance of Debt |
12
|
(6)
|
(6)
|
(5)
|
(4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other |
(0)
|
(23)
|
(24)
|
(24)
|
(24)
|
(1)
|
(10)
|
(11)
|
(12)
|
(13)
|
(4)
|
0
|
0
|
0
|
0
|
31
|
270
|
|
Cash from Financing Activities |
87
N/A
|
344
+297%
|
343
0%
|
272
-21%
|
271
0%
|
(0)
N/A
|
156
N/A
|
176
+13%
|
200
+14%
|
239
+19%
|
123
-48%
|
346
+181%
|
345
0%
|
345
+0%
|
306
-11%
|
94
-69%
|
460
+390%
|
|
Change in Cash | ||||||||||||||||||
Net Change in Cash |
84
N/A
|
318
+279%
|
307
-4%
|
227
-26%
|
213
-6%
|
(76)
N/A
|
69
N/A
|
(1)
N/A
|
(162)
-15 916%
|
(151)
+6%
|
(266)
-76%
|
20
N/A
|
(21)
N/A
|
29
N/A
|
(58)
N/A
|
(155)
-168%
|
353
N/A
|
|
Free Cash Flow | ||||||||||||||||||
Free Cash Flow |
(3)
N/A
|
(26)
-823%
|
(36)
-38%
|
(38)
-6%
|
(51)
-34%
|
(72)
-41%
|
(84)
-16%
|
(99)
-17%
|
(109)
-10%
|
(117)
-7%
|
(127)
-9%
|
(139)
-10%
|
(160)
-15%
|
(173)
-8%
|
(179)
-3%
|
(123)
+31%
|
(144)
-17%
|